Estrella Immunopharma
ESLA
15 hedge funds and large institutions have $4.99M invested in Estrella Immunopharma in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
1% less ownership
Funds ownership: 12.14% → 11.14% (-1%)
6% less funds holding
Funds holding: 16 → 15 (-1)
9% less capital invested
Capital invested by funds: $5.49M → $4.99M (-$504K)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$45K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$19.9K |
| 3 |
BlackRock
New York
|
+$15.9K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
+$4.05K |
| 5 |
Barclays
London,
United Kingdom
|
+$165 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$280K |
| 2 |
AC
Armistice Capital
New York
|
-$162K |
| 3 |
Renaissance Technologies
New York
|
-$31K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$21.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17.5K |
ESLA Hedge Fund Activity: Q2 2026 in Review
15 of the 8,330 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q2 2026, worth a combined $4.99M — down 9.2% from $5.49M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ESLA and 2 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Capital Management, adding an estimated $45K. The largest seller was Wells Fargo, exiting entirely with an estimated $280K sold.
- 15 institutional investors held Estrella Immunopharma (ESLA) as of Q2 2026, down from 16 in Q1 2026.
- Funds reported $4.99M of Estrella Immunopharma stock for Q2 2026, down 9.2% quarter-over-quarter.
- 2 funds opened new Estrella Immunopharma positions in Q2 2026 and 3 closed out, a net change of -1 holder.
- The largest Estrella Immunopharma buyer in Q2 2026 was Vanguard Capital Management, an estimated $45K added.
- The largest Estrella Immunopharma seller in Q2 2026 was Wells Fargo, an estimated $280K sold.
Based on aggregated 13F filings for Q2 2026.